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Abstract: The sponge genus Latrunculia is a prolific source of discorhabdin type 
pyrroloiminoquinone alkaloids. In the continuation of our research interest into this genus, we 
studied the Antarctic deep-sea sponge Latrunculia biformis that showed potent in vitro anticancer 
activity. A targeted isolation process guided by bioactivity and molecular networking-based 
metabolomics yielded three known discorhabdins, (−)-discorhabdin L (1), (+)-discorhabdin A (2), 
(+)-discorhabdin Q (3), and three new discorhabdin analogs (−)-2-bromo-discorhabdin D (4), (−)-1-
acetyl-discorhabdin L (5), and (+)-1-octacosatrienoyl-discorhabdin L (6) from the MeOH-soluble 
portion of the organic extract. The chemical structures of 1–6 were elucidated by extensive NMR, 
HR-ESIMS, FT-IR, [α]D, and ECD (Electronic Circular Dichroism) spectroscopy analyses. 
Compounds 1, 5, and 6 showed promising anticancer activity with IC50 values of 0.94, 2.71, and 
34.0 µM, respectively. Compounds 1–6 and the enantiomer of 1 ((+)-discorhabdin L, 1e) were 
docked to the active sites of two anticancer targets, topoisomerase I-II and indoleamine 2,3-
dioxygenase (IDO1), to reveal, for the first time, the binding potential of discorhabdins to these 
proteins. Compounds 5 and 6 are the first discorhabdin analogs with an ester function at C-1 and 6 
is the first discorhabdin bearing a long-chain fatty acid at this position. This study confirms 
Latrunculia sponges to be excellent sources of chemically diverse discorhabdin alkaloids.  
Keywords: Latrunculia; Antarctica; deep-sea sponge; molecular networking; molecular docking; 
discorhabdin 
 
1. Introduction 
Latrunculia species are cold-adapted sponges commonly found in the coastlines of the southern 
hemisphere [1−3]. The genus Latrunculia has proven to be a prolific source of structurally intriguing 
compounds from different classes, such as norsesterterpenes [4,5], callipeltins [6,7], and various 
types of pyrroloiminoquinone alkaloids [8−10]. Discorhabdins represent a large and unique 
subclass of pyrroloiminoquinone alkaloids that have been associated with the chemical defense and 
greenish to brownish coloration of the sponge [11,12]. Discorhabdins exhibit strong anticancer 
activity against many cancer types, such as human colon cancer, adenocarcinoma, and leukemia 
[13−15]. However, the mechanism of their anticancer action has been poorly studied. Indeed, only 
the farnesyltransferase enzyme [16] and hypoxia-inducible factor 1α (HIF-1α) and transcriptional 
coactivator p300 interaction [17] have been shown as potential targets of discorhabdins. 
As part of our research interest into deep-sea Latrunculia sponges from Antarctica [18], herein 
we investigated the in-depth chemistry of Latrunculia biformis, which was collected from the 
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Antarctic Weddell Sea shelf at 291 m depth. The crude organic extract of the sponge exhibited 
significant in vitro anticancer activity against six cancer cell lines. A molecular networking (MN)-
based metabolomics study on fractions obtained from the MeOH-soluble portion of the sponge 
indicated the presence of a large discorhabdin cluster with many nodes belonging to potentially 
new discorhabdins. Guided by anticancer activity and MN-based dereplication, six discorhabdin-
type alkaloids were isolated from the MeOH subextract, including three known compounds (−)-
discorhabdin L (1), (+)-discorhabdin A (2), (+)-discorhabdin Q (3) and three new discorhabdin 
derivatives, namely (−)-2-bromo-discorhabdin D (4), (−)-1-acetyl-discorhabdin L (5), and (+)-1-
octacosatrienoyl-discorhabdin L (6). Since the amounts of the isolated compounds were very minor, 
only compounds 1, 5 and 6 could be tested for their anticancer activity against the human colon 
cancer cell line HCT-116. We applied a structure-based docking approach on all isolated 
compounds and the enantiomer of 1 (1e) against two cancer targets reported for 
pyrroloiminoquinone alkaloids, i.e., topoisomerase I–II and indoleamine 2,3-dioxygenase IDO1 
[19−21] to predict their anticancer potential and to suggest potential molecular mechanism(s) of 
action. This study reports MN and bioactivity-guided isolation of compounds 1−6, their structure 
elucidation, and biological activities with potential target identification for their anticancer activity. 
2. Results 
2.1. Bioactivity and Molecular Networking-guided Purification and Structural Elucidation 
The olive green-colored sponge material was freeze-dried and successively extracted with 
water, MeOH, and dichloromethane (DCM) subsequently. The combined organic extract was 
submitted to bioactivity screening against six cancer cell lines, where it showed significant activity 
with IC50 values ranging from 4.0 to 56.2 µg/mL (Table 1). The solvent partitioning of the crude 
organic extract between MeOH and n-hexane yielded the MeOH (M) and the n-hexane subextracts. 
The M subextract demonstrated strong anticancer activity (Figure 1) and was further fractionated 
over a C18 SPE cartridge. The anticancer activity was tracked to six SPE fractions, M2–M5, M7, and 
M8 (Figure 1). 
Table 1. Anticancer activity of the L. biformis crude extract. The IC50 values are in µg/mL. Positive 
control doxorubicine. 
Sample A-375 HCT-116 A-549 MB-231 Hep G2 HT-29 
Crude extract 17.4 4.8 56.2 46.8 18.2 4.0 
Positive control 0.13 10.6 31.4 15.2 14.6 3.0 
In order to prioritize the isolation workflow towards undescribed molecules with potential 
anticancer properties, we acquired tandem UPLC-QToF-MS/MS (positive-ion mode) data on these 
six active fractions. The generated MS/MS (MS2) data were uploaded to the publicly available 
Global Natural Product Social Molecular Networking (GNPS) platform (http://gnps.ucsd.edu) and 
analyzed following the molecular networking (MN) online workflow [22]. Software Cytoscape 
(Version 3.61) was used to visualize the resulting networks. The automated dereplication on GNPS 
platform did not annotate any pyrroloiminoquinone alkaloids. Hence, compound annotation was 
based on manual dereplication by comparing the predicted molecular formulae against multiple 
public or commercially available databases.  
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Figure 1. In vitro activity of MeOH subextract (M) and its C18 solid phase extraction (SPE) fractions 
(M1–M8) against six cancer cell lines. Test concentration: 100 µg/mL. Positive control: Doxorubicine. 
Solvent control: 0.5% DMSO. 
After a comprehensive examination of the global MN of the SPE fractions, two clusters 
attracted our attention (Figure 2). Cluster 1 contained five nodes, four of which were annotated as 
known molecules discorhabdin L [13], its analog, discorhabdin D [23], and 1-methoxydiscorhabdin 
D [19], leaving the node at m/z 368.0380 to be a putatively new derivative (Figure 2). From this 
cluster, we were able to purify (−)-discorhabdin L (1), but failed to purify the potentially new 
discorhabdin analog (m/z 368.0380) due to its very minor quantity. 
With 21 nodes, cluster 2 was the biggest in the generated MN, which can be further divided 
into three subclusters (Figure 2). Based on the elemental composition analysis, MS/MS 
fragmentation patterns, and biological source, two brominated alkaloids discorhabdin A [24] and 
discorhabdin G [25] were identified in subcluster 3. However, only discorhabdin A (2) was isolated 
in sufficient amounts for NMR and other spectroscopic analyses. Discorhabdin H2 [26] was the only 
annotated compound in subcluster 2. Unfortunately, neither this compound nor the remaining 
nodes that represent potentially new discorhabdin analogs could be purified in sufficient quantity.  
 
Figure 2. Molecular cluster observed in SPE fractions of L. biformis MeOH subextract. Numbers 
within the nodes indicate parent ions, and edge thickness represents the cosine similarity between 
nodes. Red nodes: Discorhabdin esters; Grey nodes: Other discorhabdin analogs. 
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The subcluster 1 (of cluster 2) contained four nonbrominated nodes at m/z 394.0560, 408.0710, 
422.085, and 436.1010 connected with thick edges, indicating their high structural similarity. 
Elemental composition analysis revealed the difference of a CH2 unit between these ions (Figure 2, 
in red). In-depth analysis of their MS/MS spectra revealed the presence of the same MS fragment 
(m/z 352.0766, C18H14N3O3S) in all four compounds, suggesting these compounds to be discorhabdin 
alkaloids bearing an alkyl chain with varying lengths. From subcluster 1, we isolated the compound 
with m/z 394.0560 and identified it as a new metabolite, (−)-1-acetyl-discorhabdin L (5), as discussed 
later. 
In addition, we purified three compounds, namely the known compound (+)-discorhabdin Q 
(3) as well as two new compounds, namely (−)-2-bromo-discorhabdin D (4) and (+)-1-
octacosatrienoyl-discorhabdin L (6), which did not appear in the MN because of the low intensity of 
their MS fragments. The enantiopurity of all purified compounds was further checked individually 
by RP-DAD-HPLC on an analytical chiral column. The sharp single peak in the UV chromatograms 
confirmed the enantiopurity of 1–6.  
The structure of compound 1 was elucidated as (−)-(1R,2S,6R,8S)-discorhabdin L [13], based on 
comparison of its 1D and 2D NMR data including NOESY spectrum (Tables 2 and 3, 
Supplementary Figures S1−S6). The specific rotation of compound 1 ([α]20D = −71, c 0.1, MeOH) 
showed the same sign as that reported for (−)-discorhabdin L ([α]20D = −240, c 0.0125, MeOH) [26]. In 
order to confirm the absolute configuration of compound 1, the ECD (Electronic Circular Dichroism) 
spectrum was run. The experimental ECD spectrum of 1 (Supplementary Figure S8) was essentially 
identical to the ECD spectrum of (−)-(1R,2S,6R,8S)-discorhabdin L [26]. Hence, compound 1 was 
unambiguously characterized as (−)-(1R,2S,6R,8S)-discorhabdin L. 
 
Figure 3. Chemical structures of compounds 1–6. 
Compound 2 exhibited the same 1H and 13C NMR resonances (Supplementary Figures S9 and 
S10) as (+)-discorhabdin A [24,27]. The analysis of its COSY, HSQC, and HMBC spectra 
(Supplementary Figures S10–S12) supported the same planar structure as discorhabdin A and 
NOESY spectrum confirmed the relative configuration of three stereocenters (Supplementary 
Figure S13). The specific rotation of compound 2 ([α]20D = +197, c 0.01, MeOH) exhibited the same 
sign as (+)-discorhabdin A ([α]20D = +400, c 0.05, MeOH) [24]. An early X-ray crystal analysis has 
confirmed the configuration of the chiral centers within (+)-discorhabdin A as 5R,6S,8S [27]. Thus, 
compound 2 was identified as (+)-(5R,6S,8S)-discorhabdin A (Figure 3).  
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Compound 3 was identified as the known compound discorhabdin Q, based on its 1D and 2D 
NMR data (Supplementary Figures S15–S20), which were in good agreement with those reported in 
the literature [26]. The examination of the 1H-1H NOESY spectrum of 3 (Supplementary Figure S19) 
allowed the assignment of the relative configuration of two stereocenters. Compound 3 exhibited a 
specific rotation value ([α]20D = +568, c 0.1, MeOH), which was similar both in the magnitude and 
sign to that observed for (+)-(6S,8S)-discorhabdin Q ([α]20D = +720, c 0.025, MeOH) [26], hence we 
concluded compound 3 as (+)-(6S,8S)-discorhabdin Q. 
Table 2. 1H NMR data of compounds 1, 4, 5, and 6 in CD3OD (trifluoroacetic acid (TFA) salts, 600 
MHz, δ in ppm). 
NO. 
1 4 5 6 
δH, Mult. (J in Hz) δH, Mult. (J in Hz) δH, Mult. (J in Hz) δH, Mult. (J in Hz) 
1 4.63 d (3.6) 
3.58 d (13.3) 
3.23 d (13.3) 
5.79 d (3.6) 5.79 d (3.6) 
2 4.15 d (3.6) - 4.36 d (3.6) 4.35 d (3.6) 
4 6.14 s 6.14 s 6.23 s 6.23 s 
7α 2.57 dd (1.3, 12.0) 2.66 dd (1.5, 12.1) 2.63 dd (1.4, 12.1) 2.64 d (1.2, 12.1) 
7β 2.96 dd (3.6, 12.0) 2.84 dd (3.5, 12.1) 2.81 dd (3.7, 12.1) 2.76 dd (3.6, 12.1) 
8 5.59 dd (1.3, 3.6) 5.68 dd (1.5, 3.5) 5.61 dd (1.4, 3.7) 5.61 dd (1.2, 3.6) 
14 7.11 s 7.14 s 7.13 s 7.13 s 
16 
3.19 ddd (7.5, 13.0, 16.7) 
3.06 ddd (3.0, 6.9, 16.7) 
3.10 m 
3.21 ddd (6.9, 7.5, 16.6) 
3.08 ddd (2.9, 6.9, 16.6) 
3.22 ddd (6.8, 7.3, 16.6) 
3.08 ddd (2.7, 6.8, 16.6) 
17 4.02 ddd (3.0, 7.5, 14.2) 4.62 ddd (2.1, 5.6, 13.8) 4.04 ddd (2.9, 7.5, 13.8) 4.04 ddd (2.7, 7.3, 13.7) 
 3.91 ddd (6.9, 13.0, 14.2) 3.66 td (6.3, 13.8) 3.93 td (6.9, 13.8) 3.93 td (6.8, 13.7) 
2’ - - 2.15 s 2.44 td (1.5, 7.5) 
3’ - - - 1.69 m 
4’ - - - 2.10 m 
5’ - - - 5.34 m 
6’ - - - 5.44 m 
7’ - - - 2.08 m 
8’ - - - 2.08 m 
9’ - - - 5.37 m 
10’ - - - 5.34 m 
11’–
27’ 
- - - 
1.25–1.40 m;  
2.00–2.06 m; 5.36 m 
28’ - - - 0.90 t (7.0) 
Compound 4 was obtained as a greenish film. The isotopic pattern of the molecule ion peaks 
(1:1 ratio) was indicative for the presence of one bromine atom in this molecule. The molecular 
formula of C18H1379BrN3O2S was established by the pseudo-molecular ion peak at m/z 413.9913 [M + 
H]+ in the HR-ESIMS (Supplementary Figure S27) spectrum, requiring 14 degrees of unsaturation. 
The 1H NMR data (Table 2, Supplementary Figure S22) together with HSQC spectrum 
(Supplementary Figure S23) revealed the presence of three methine resonances at δH 7.14 (H-14, s), 
δH 6.14 (H-4, s), and δH 5.68 (H-8, dd, J = 1.5, 3.5 Hz), four methylene groups corresponding to H2-17 
(δH 3.66 and 4.62), H2-1 (δH 3.23 and 3.58), H2-16 (δH 3.10), and H2-7 (δH 2.66 and 2.84). The 13C NMR 
spectrum (Table 3) showed 18 carbon signals including 4 methylenes (δC 20.0, 38.7, 42.4, and 50.2), 3 
methines (δC 63.1, 110.9, and 126.0), and 11 quaternary carbons (δC 44.5, 78.1, 100.4, 119.3, 122.2, 
124.0, 148.2, 150.2, 165.4, 172.8, and 176.4). By comparison with the data reported for discorhabdins 
[13,23], the three low-field quaternary carbon signals at δC 176.4, 172.8, and 165.4 were tentatively 
assigned to C-3, C-5, and C-11, respectively, while the high-field quaternary carbon at δC 44.5 was 
assigned to C-6. The COSY correlation between H2-16 and H2-17, together with the additional 1H - 
13C HMBC correlations between H-14/C-12, C-21, C-11; H2-16/C-14, C-21; H2-17/C-15, C-19 
confirmed the pyrroloiminoquinone motif [13,23]. Similarly, the homonuclear COSY correlation 
between H2-7 and H-8, and the HMBC correlations between H2-1/C-2, C-3, C-6, C-20; H-4/C-2, C-3, 
C-6; and H2-7/C-5, C-6, C-20 suggested the position of the carbonyl group (δC 176.4) at C-3, and the 
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position of the methylene (δC 42.4) at C-1 (Figure 4A). A further HMBC coupling between H-8 and 
C-5 was indicative of a thioether bridge between C-8 and C-5, while the HMBC correlation between 
H2-17 and C-2 established the bridge between N-18 and C-2 (Figure 4A). All these data, plus the 
lack of any further spin coupling observed for H2-1, allowed the placement of the bromine atom on 
the remaining quaternary carbon, C-2. Thus the planar structure of compound 4 was elucidated as 
2-bromo-discorhabdin D.  
Table 3. 13C NMR data of compounds 1, 4, 5, and 6 in CD3OD (150 MHz, δ in ppm). 
Position 
1 4 5 6 
δC δC a δC δC 
1 68.5 (CH) 42.4 (CH2) 69.6 (CH) 69.5 (CH) 
2 67.8 (CH) 78.1 (C) 64.6 (CH) 64.6 (CH) 
3 184.8 (C) 176.4 (C) 183.1 (C) 183.0 (C) 
4 114.1 (CH) 110.9 (CH) 114.4 (CH) 114.4 (CH) 
5 171.5 (C) 172.8 (C) 171.2 (C) 171.1 (C) 
6 48.6 (C) 44.5 (C) 47.0 (C) 47.1 (C) 
7 37.4 (CH2) 38.7 (CH2) 37.4 (CH2) 37.5 (CH2) 
8 63.7 (CH) 63.1 (CH) 63.5 (CH) 63.5 (CH) 
10 148.6 (C) 148.2 (C) 149.0 (C) 149.1 (C) 
11 167.5 (C) 165.4 (C) 167.1 (C) 167.1 (C) 
12 125.6 (C) 124.0 (C) 125.6 (C) 125.6 (C) 
14 127.2 (CH) 126.0 (CH) 127.4 (CH) 127.4 (CH) 
15 119.2 (C) 119.3 (C) 119.4 (C) 119.4 (C) 
16 20.6 (CH2) 20.0 (CH2) 20.7 (CH2) 20.7 (CH2) 
17 52.8 (CH2) 50.2 (CH2) 52.9 (CH2) 52.9 (CH2) 
19 150.3 (C) 150.2 (C) 150.4 (C) 150.4 (C) 
20 101.8 (C) 100.4 (C) 100.6 (C) 100.6 (C) 
21 122.7 (C) 122.2 (C) 122.7 (C) 122.7 (C) 
1’ -  171.0 (C) 173.6 (C) 
2’ -  20.4 (CH3) 34.0 (CH2) 
3’ -  - 25.8 (CH2) 
4’ -  - 27.5 (CH2) 
5’ -  - 129.7 (CH) 
6’ -  - 131.7 (CH) 
7’ -  - 28.4 (CH2) 
8’ -  - 28.4 (CH2) 
9’ -  - 130.1 (CH) 
10’ -  - 130.8 (CH) 
11’–25’ -  - 
28.1-30.9 (CH2); 
130.9 (CH); 131.4 
(CH) 
26’ -  - 32.9 (CH2) 
27’ -  - 23.7 (CH2) 
28’ -  - 14.5 (CH3) 
a Extracted from HSQC and HMBC spectra. 
Compound 4 is a configurationally rigid molecule with seven rings and three stereocenters at 
C-2, C-6, and C-8. The relative configurations of these stereogenic centers were proposed by the 
NOE correlations as shown in Figure 4B. The specific rotation value of 4 ([α]20D = −246, c 0.05, MeOH) 
is opposite to that of (+)-(2S,6R,8S)-discorhabdin D ([α]20D = +80, c 0.025, MeOH) [26]. The 
experimental ECD spectrum of compound 4 (Supplementary Figure S8) showed the same cotton 
effects as compound 1 (−)-(1R,2S,6R,8S)-discorhabdin L. So it is reasonable to assume that 
compound 4 is (−)-(2R,6R,8S)-2-bromodiscorhabdin D.  
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A B 
Figure 4. Key 2D NMR correlations observed for compound 4. (A) The COSY (in bold), key H→C 
HMBC (arrows); (B) key H→H NOESY correlations (dashed line).  
Compound 5 was obtained as a green film. Its molecular formula C20H16N3O4S was deduced by 
HR-ESIMS (m/z 394.0816, [M + H]+) indicating 15 degrees of unsaturation. The FT-IR spectrum of 
compound 5 displayed the characteristic ester carbonyl absorption band at vmax 1747 cm-1 and other 
similar bands as compound (1) at vmax 1653, 1621, 1560, 1528, 1412, and 1201 cm-1. The 1H and 13C 
NMR spectra of 5 ( Table 2; Table 3) revealed high similarity with 1, with the only difference being 
the presence of an extra acetyl group in 5 (δH 2.15; δC 171.0 and δC 20.4). The site of esterification was 
identified as C-1, based on strong HMBC correlations between H-1/C-1’ and a weaker HMBC 
coupling between H-2’/C-1 (Figure 5A). Thus, the planar structure of compound 5 was confirmed as 
1-acetyl-discorhabdin L. The analysis of the full 2D NMR dataset (COSY, HSQC, and HMBC) 
further confirmed that the planar structure of compound 5 (Figure 5A). The relative configuration 
of compound 5 was elucidated by examining its NOESY spectrum (Figure 5B). The COSY 
correlation between H-4/H-7 (Supplementary Figure S32) indicated a planar ‘‘W’’ arrangement [28] 
of the molecule as observed in discorhabdins L [13] and D [23], thus allowing the assignment of the 
resonance at δH 2.63 to H-7α [13]. The stereochemistry at C-1 was proposed by the strong NOE 
correlation (Figure 5B) between H-1/H-7α. To establish the absolute configuration of (−)-5, its 
experimental ECD spectrum was compared with that of (−)-(1R,2S,6R,8S)-discorhabdin L (1) 
(Supplementary Figure S8). The same Cotton effects observed at 290, 360, and 440 nm for both 
compounds established the absolute configuration of 5 as 1R,2S,6R,8S. Finally, the comparison of 
the specific rotation values of compounds 1 ([α]20D = −71, c 0.1, MeOH) and 5 ([α]20D = −420, c 0.01, 
MeOH) identified the structure of 5 as (−)-(1R,2S,6R,8S)-1-acetyl-discorhabdin L. 
 
 
(A) (B) 
Figure 5. Key 2D NMR correlations observed for compound 5. (A) The COSY (in bold), key H→C 
HMBC (arrows); (B) key H→H NOESY correlations (dashed line). 
The most nonpolar component, compound 6, was obtained as a green film with an [α]20D value 
of + 541 (c 0.1, MeOH). It showed a molecular ion peak at m/z 752.4452 [M + H]+ in the HR-ESIMS 
spectrum. The molecular formula of C46H62N3O4S was deduced from its 13C NMR and HR-ESIMS 
data (Table 3 and Supplementary Figure S41), indicating 18 degrees of unsaturation. The FT-IR 
spectrum contained absorption bands typical of an ester function (vmax 1739 cm-1) and an alkyl chain 
(vmax 2927 and 2855 cm-1, -CH2 and -CH3 stretching bands). Comparison of the 1D-NMR data of 6 
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with those of 1 and 5 (Tables 2 and 3) suggested 6 to be another analog of discorhabdin L esterified 
with a long chain fatty acid (δC 25–35 ppm; δH 1.2–1.4 ppm), which made this molecule very 
lipophilic. The discorhabdin L core structure that was evident from the 1D and 2D NMR data of 6 
(Tables 2 and 3; Figure 6) accounted for 14 degrees of unsaturation. The additional ester carbonyl at 
δC 173.6 and six sp2 carbons belonging to three double bonds at δC 129.7, 130.1, 130.8, 130.9, 131.4, 
and 131.7 (Supplementary Figure S36) accounted for the remaining 4 degrees of unsaturation. 
Hence, we concluded that the alkyl chain was an unbranched octacosa-triene-oic acid (28:3) (Tables 
2 and 3). The HMBC correlation between H-1 (δH 5.79) and C-1’ (δC 173.6) supported the attachment 
of the fatty acid at C-1 (Figure 6A). The geometry of these three double bonds in the fatty acid 
portion was elucidated by analyzing the 13C NMR chemical shifts of the six carbons neighboring the 
double bonds [29]. Carbon atoms adjacent to cis double bonds resonate around δC 26.0–28.5, 
whereas those adjacent to trans double bonds appear at higher chemical shift values, namely δC 
29.5–38.0 [29]. The observed 13C NMR shifts in (+)-6 at δC 27.5, 28.1, 28.2 (x 2), 28.4 (x 2) confirmed 
the cis (Z) configuration of all three double bonds in the fatty acid part (Table 3). The COSY 
correlations from C-2’ to C-10’ and HMBC correlations between H2-2’/C-1’, C-4’; H2-3’/C-1’, C-4’, C-
5’; H-6’/C-4’, C-7’, C-8’; H2-7’/C-9’ (Figure 6A) allowed us to corroborate the position of two 
unsaturations at C-5’ and C-9’, and to assign the C-1’ to C-10’ portion of the fatty acid (Figure 3). 
Comparison of the 1D NMR data of (+)-6 with the literature [30] also supports the presence of a ∆5,9 
unsaturated fatty acid. This finding is not surprising since these cis,cis-5,9-dienoic lipids are 
common in sponges [31]. The chemical shift values of C-26’, C-27’ and C-28’ (Table 3) were also 
assigned by comparison with the literature data [32]. Thus, compound (+)-6 was identified as C-1 
octacosatrienoic acid (C28:3) ester of (−)-discorhabdin L (Figure 3). Due to availability of very minor 
amount of the compound (0.2 mg) and the failed attempts to improve the highly overlapped NMR 
signals through different solvents (e.g., MeOD, CDCl3, and DMSO-d6), we were unable to confirm 
the position of the third double bond. However, we believe that the lipid residue in 6 is related to 
the well-known 5Z,9Z demospongic acids bearing another double bond at C-17, or C-19, or C-23 
[31]. 
On the basis of a strong NOE correlation between H-1 and H-7α (Figure 6B), as well as the 
other NOE correlations shown in Figure 6B, the relative configuration of 6 was elucidated to be the 
same as compounds 1 and 5. The absolute configuration of 6 was established by comparing its 
experimental ECD spectrum with those of 1 and 5 (Supplementary Figure S8). Based on the 
opposite sign of the specific rotation value of 6 ([α]20D = +541, c 0.1, MeOH) in comparison to 
compounds 1 ([α]20D = −71, c 0.1, MeOH) and 5 ([α]20D = −420, c 0.01, MeOH), 6 was identified as (+)-
(1R,2S,6R,8S)-1-octacosatrienoyl-discorhabdin L (Figure 3). 
  
(A) (B) 
Figure 6. Key 2D NMR correlations observed for compound 6. (A) The COSY (in bold), key H→C 
HMBC (arrows); (B) key H→H NOESY correlations (dashed line). 
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2.2. In Vitro Bioactivity Tests and Molecular Docking on Purified Compounds 
Anticancer activity of the pyrroloiminoquinone-type alkaloids has been the main driving force 
for isolation of these intriguing structural types. Due to low quantities of the isolated compounds, 
we were only able to assess the in vitro anticancer activities of compounds 1, 5, and 6 against one 
cell line. We used HCT-116 colon cancer cells for testing, because of the observed high activity of 
the MeOH subextract and SPE fractions (Table 1), plus the availability of literature data for (−)-
discorhabdin L (1) against this cell line (IC50 value 6.2 µM) [17]. In the current study, compound 1 
showed IC50 value of 0.94 µM (equal to 0.33 µg/mL). The compound 5 displayed promising activity 
with an IC50 value of 2.71 µM (= 1.1 µg/mL), while compound 6 was only modestly active against 
the same cell line (IC50 value 34.0 µM, equal to 25.6 µg/mL). These results indicate that C-1 OH 
function is important for anti-colon cancer activity and the substitution of the C-1 OH group, 
especially with a long chain fatty acyl function is not favored.  
Limited by the amounts of the isolated compounds, we performed a molecular modeling study 
(using Schrödinger software Maestro; www.schrodinger.com) on compounds 1–6 and (+)-
discorhabdin L (1e), the (+) enantiomer of compound 1, against two known anticancer targets 
(topoisomerase I/II, indoleamine 2,3-dioxygenase IDO1) to estimate their potential anticancer 
activity and mechanism(s) of action. Where possible, based on suitable pdb structures, docking 
experiments were performed. We prepared available relevant pdb protein structures, removed the 
original ligands, and generated receptor grids. Small molecule 3D structures of the compounds 
containing a quaternary nitrogen were energetically minimized and possible tautomers/protonated 
states were evaluated (LigPrep, counter ion not specified). Next, we docked the optimized ligand 
structures into respective active sites (Glide SP). Calculated 3D binding modes were illustrated, or 
presented as 2D ligand-interaction diagrams, for clarity. 
Docking of compounds 1–5 into the active site of topoisomerase I (pdb 1T8I) yielded plausible 
binding modes (Figure 7), while no binding pose could be calculated for compound 6, due to the 
sterically demanding side chain that did not fit into the tight binding pocket). Compared to the 
original ligand camptothecin, the flat, partly aromatic core of the discorhabdins 1–5 intercalated 
into the DNA part thereby forming aromatic π-π-stacking interactions while also addressing H-
bonds towards residues of the topoisomerase I protein. Similar results were obtained by docking 
experiments with topoisomerase II (pdb 3QX3, original ligand etoposide) suggesting these proteins 
to be anticancer targets for the compounds 1–5. Molecular docking study performed (in analogy to 
the procedure described above) on compound 1e, which was reported to exhibit strong in vitro 
cytotoxicity [33], revealed a binding mode in the active site of topoisomerase I, too (Figure 7). 
Comparable to 1, the flat core forms a DNA-intercalating complex, but the ligand is distorted by 
180°. Thus, the binding modes of both compounds, 1 and 1e, suggest those ligands to be rather non-
specific DNA intercalators. 
We also performed docking experiments with another reported target for 
pyrroloiminoquinone alkaloids, namely the indoleamine 2,3-dioxygenase (IDO1) enzyme for which 
structural data including ligand–protein complexes are available. As cofactor to mediate 
physiological substrate oxidation, IDO1 contains a heme moiety and ligands typically form 
interactions by complexing the iron central atom. Examples for such IDO1 inhibitors and relevant 
interacting moieties include NLG919 derivative (imidazole-like nitrogen in pdb 5EK2) or ligand 
INCB14943 (hydroxylamidine moiety in pdb 5XE1). Since the compounds lack comparable nitrogen 
functionalities to able to interact with heme in a similar manner, docking of the compounds into 
these active sites revealed no plausible binding modes. However, recent reports demonstrated that 
another class of potent IDO1 inhibitors such as FXB-001116 (pdb 6AZW) and BMS-978587 (pdb 
6AZV) bind to the IDO1 apo structure with high affinity, thereby displacing the heme moiety. 
Accordingly, we performed docking experiments of compounds 1–6 and 1e using the apo-protein. 
This approach suggested possible binding modes for compounds 1–4 and 1e in the apo active site of 
IDO1 (Figure 8), but not for the sterically more demanding compounds 5 and 6. 
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Figure 7. (A) Calculated 3D binding modes of compounds 1–5 and 1e in the active site of 
topoisomerase I (pdb 1T8I) also containing a DNA molecule (colored in red) with a single strand 
break; (B) corresponding 2D ligand interaction diagrams showing key interactions of compounds 1–
5 and 1e towards topoisomerase I and DNA.  
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Figure 8. 3D binding poses (A) and ligand interaction diagrams (B) of compounds 1–4 and 1e in the 
active site of IDO1 (pdb 6AZW). Key interactions are shown. The binding pocket is shown in a 
similar orientation, respectively. Ligand docking revealed plausible binding poses for compounds 
1–4 and 1e, but not for compounds 5 and 6. 
Inspecting the docking poses of 1 in the above-mentioned protein structures on a molecular 
level pointed towards a key role for the sterically defined OH-function in 1, as it mediates an H-
bond towards Ala264. Another key H-bond interaction occurred between aromatic NH of 1 towards 
Ser167 (Figure 8). Compound 1 shows a rather planar core, anchoring the ligand with a strong 
shape-fit into the tight binding pocket. Relative to this core, the thioether bridge sits almost 
rectangular on top, occupying a lipophilic area within the binding site, flanked by residues 
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including Val350, Phe226, and Leu384. Within these small sets of compounds, docking of 1 reveals 
the optimal pose. We also docked (+)-discorhabdin L (1e), the enantiomer of 1, into the active site of 
IDO1 (in analogy to the procedure described above). Interestingly, the flat core was found to again 
fill the rather flat pocket. In comparison to 1, the core sits upside down in 1e, with the key H-bond 
towards Ala264 being maintained. Accordingly, the NH-bond towards Ser167 was lost, but the 
aromatic system formed a π-interaction to Tyr126 (Figure 8). These poses suggest the flat aromatic 
core of this type of compounds to be the main requisite to bind into the pocket. Furthermore, 
stereochemistry seems to play a minor role in binding. Thus, it can be assumed the compounds are 
rather non-specific IDO1-ligands. 
The calculated binding mode of compound 4 yielded a shifted orientation of the core, with 
only one H-bond towards Ser167 (Figure 8). In contrast, compounds 5 and 6 gave no plausible 
docking solutions, again due to the sterically demanding ester moieties, thus also preventing H-
bonding by OH towards Ala264.  
In summary, the molecular modeling data suggested plausible binding modes for compounds 
1–5 in the target structure of topoisomerase I, and for compounds 1–4 towards IDO1, respectively. 
However, it is well possible that this class of compounds bind further key anticancer targets, 
contributing to their cytotoxic potential. 
3. Discussions 
Since the discovery of discorhabdin C from a New Zealand Latrunculia sp. in 1986 [8], more 
than 40 discorhabdin analogs have been reported from different marine sponge genera [34]. Some 
discorhabdins contain bromination at C-2, C-4, or C-14 positions (e.g., discorhabdin A, 
discorhabdin C, 14-bromodihydrodiscorhabdin C) [8,23,24,35], some possess a sulfur bridge 
between C-5 and C-8 (e.g., discorhabdin B, discorhabdin Q) [24,36]. A few discorhabdins (e.g., 
discorhabdin L, discorhabdin D) are heptacyclic through the formation of an extra bridge between 
C-2 and N-18 [13,24]. Of the six compounds obtained in the current study, two of them (5 and 6) are 
(−)-discorhabdin L esters. Compound 6 is a triunsaturated C28 fatty acid ester of discorhabdin L. To 
our knowledge this is the first discorhabdin alkyl ester structure being reported from a marine 
sponge. Notably, Zou et al. (2013) reported atkamine, a new, large pyrroloiminoquinone scaffold 
containing a fused epoxybenzazepin and bromophenol groups connected with a cyclic sulfide ring 
[37]. Between the former and the latter rings, there is a substitution with a monosaturated C20 alkyl 
chain. The authors suggested this alkyl group to originate from (Z)-15-docosenoic acid, a fatty acid 
commonly found in sponge species that was possibly incorporated in the very early biosynthesis 
stages of atkamine [37]. Compounds 5 and 6 isolated in this study instead bear an esterification at 
C-1 position of the pyrroloiminoquinone ring system. Compound 5 is an acetyl ester of (−)-
discorhabdin L, while 6 is an ester of discorhabdin L with an unbranched octacosatrienoic acid. 
Marine sponges, especially demosponges, are regarded as one of the richest sources of long-chain 
fatty acids (LCFAs; i.e., C23–34) [38,39]. The octacosatrienoic acid (C28:3) has been reported from 
marine sponges and corals [40−42], but not from any Latrunculia species. The only study that 
analyzed the FAs composition of Antarctic Latrunculia sponges in 2015 showed that Antarctic L. 
biformis contained diverse common and LCFAs (C16, C18), however longer chain unsaturated FAs 
were not found [43]. This is the first report of a discorhabdin-LCFA ester from nature, and the 
current study adds three new and intriguing analogs to the list of discorhabdin class alkaloids. 
Discorhabdins have been repeatedly studied for their in vitro anticancer activity [10,13,14]. 
Limited by the strong cytotoxicity and the supply issue, no molecule from this chemical family has 
ever proceeded to further clinical studies. A few structure–activity relationship studies (SARs) 
associated with discorhabdins have been conducted, revealing that the ring closure by a bridge 
between C2 and N18 can significantly reduce the cytotoxicity, while a substitution at C-1 (i.e., OMe, 
NH2) can enhance the anticancer activity [19,26]. The discovery of C-1 esters of discorhabdin L with 
good to moderate inhibitory activity against HCT-116 cell line here provides further insights for the 
SARs of discorhabdins.  
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Although many discorhabdins are associated with anticancer/cytotoxic activity, little is known 
on their exact mechanism(s) of action. Wada et al. (2011) evaluated (+)-discorhabdin A and its 
synthetic oxa analog for inhibition against a set of anticancer target enzymes, such as protein 
kinase, histone deacetylase, farnesyltransferase, telomerase, and proteasome [16]. (+)-Discorhabdin 
A and its synthetic oxa analog weakly inhibited the farnesyltransferase enzyme (IC50 > 10µM) [16]. 
Geoy et al. recently tested the HIF-1α/p300 inhibition activity of several discorhabdins, including 
(−)-discorhabdin L (IC50 value 0.73 μM) concluding them to be a novel class of HIF-1α/p300 
inhibitors [17]. In the current study, an in silico molecular modeling study revealed the plausible 
binding modes of discorhabdins in two additional cancer target enzymes, topoisomerase I/II and 
IDO1. 
In summary, guided by the anticancer activity and MN-based metabolomics, the Antarctic 
deep-sea sponge L. biformis led to the isolation and characterization of three known and three new 
discorhabdin alkaloids. Despite the small amounts of the extract and fractions that hampered the 
isolation of many further new discorhabdins, MN-based metabolomics proved useful for 
identification of chemical inventory of the sponge in early stages. Two compounds were a new type 
of discorhabdin esters that yielded meaningful SARs in comparison to the parent compound 
discorhabdin L. Mechanistic studies based on molecular modeling showed, for the first time, the 
potential binding of discorhabdins to additional anticancer targets that may be involved in their 
anticancer activity.  
4. Materials and Methods  
4.1. General Procedures  
Specific rotation of compounds 1–6 were measured on a Jasco P-2000 polarimeter (Jasco, 
Pfungstadt, Germany). FT-IR spectra were recorded using a PerkinElmer Spectrum Two FT-IR 
spectrometer (PerkinElmer, Boston, MA, USA). UV spectra were run on a NanoVue Plus 
spectrophotometer (GE Healthcare, New York, NY. USA). ECD spectra were run in MeOH on a J-
810 CD spectrometer (Jasco, Pfungstadt, Germany). NMR spectra were obtained on a Bruker AV 
600 spectrometer (600 and 150 MHz for 1H and 13C NMR, respectively, Bruker®, Billerica, MA, USA) 
equipped with 5.0 mm Shigemi tube (SHIGEMI, Co., LTD., Tokyo, Japan). The residual solvent 
signals were used as internal references: δH 3.31/δC 49.0 ppm (MeOD), and δH 2.50/δC 39.51 ppm 
(DMSO-d6). 4-Dimethyl-4-silapentane-1-sulfonic acid (DSS) served as the internal standard. 
HRMS/MS data were recorded on a Waters Xevo G2-XS QTof Mass Spectrometer (Waters®, Milford, 
MA, USA) coupled to a Waters Acquity I-Class UPLC system (Waters®, Milford, MA, USA). HR-
ESIMS was recorded on micrOTOF II-High-performance TOF-MS system (Bruker®, Billerica, MA, 
USA) equipped with an electrospray ionization source. Solid phase extraction (SPE) was performed 
on the Chromabond SPE C18 column cartridges (6 mL/2000 mg, Macherey-Nagel, Duren, Germany). 
HPLC separations were performed on a VWR Hitachi Chromaster system (VWR International, 
Allison Park, PA, USA) consisting of a 5430-diode array detector (VWR International, Allison Park, 
PA, USA), a 5310-column oven, a 5260 autosampler, and a 5110 pump combined in parallel with a 
VWR evaporative light scattering detector (ELSD 90, VWR International, Allison Park, PA, USA). 
The eluents used for HPLC separations were H2O (A) and MeCN (B). Routine HPLC separations 
were performed on a semi-preparative C18 monolithic column (Onyx, 100 × 10 mm, Phenomenex, 
Torrance, CA, USA) and an analytical synergi column (250 × 4.6 mm, Phenomenex, Torrance, CA, 
USA). A chiral cellulose-1 column (Lux 5µ, 250 × 4.6 mm, Phenomenex, Torrance, CA, USA) was 
used for checking the enantiopurity of each purified compound. The organic solvents used for 
UPLC-QToF-MS/MS analyses were ULC/MS grade (Biosolve BV, North Brabant, Netherlands) and 
HPLC grade (ITW Reagents, Darmstadt, Germany) for HPLC isolation processes. The water used 
was MilliQ-water produced by Arium® Water Purification Systems (Sartorius, Göttingen, Germany). 
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4.2. Sponge Material 
The sponge was collected in 2015/2016 during the Expedition PS96 of the Research Vessel 
POLARSTERN to the southern Weddell Sea (Antarctica). The sponge was collected by an Agassiz 
trawl at a depth of −291 m, and was fixated immediately after collection. Specimens were cleaned, 
pre-sorted, photographed, and transferred into buckets with cold seawater as soon as the catch was 
on deck. Subsamples were transferred into pure ethanol (96%) and the main parts were frozen at 
−20 °C. The sponges were transported to the Senckenberg Research Institute and Nature Museum in 
Frankfurt am Main, Germany. Tissue samples were taken and skeletal preparations were made for 
transmission light microscopy and SEM, according to standard protocols [44]. For taxonomic 
examination, the sponge spicules were mounted on microscope slides and studied by light 
microscopy and by SEM. Based on comparative morphology of skeletal characters, the sponge was 
identified as Latrunculia biformis, which is a common species in the Antarctic deeper shelf areas. For 
identification, the World Porifera Database [45] and relevant literature were used. A specimen (SMF 
12109) is deposited in the Porifera collection of Senckenberg Research Institute and Nature 
Museum, electronically inventoried. The data are online available in the SESAM database. 
4.3. Extraction and Isolation  
The sponge material (43.615 g, frozen weight) was cut into small pieces and freeze-dried 
(Martin Christ, Osterode am Harz, Germany). The lyophilized biomass (5.809 g) was extracted at 
room temperature with water (3 × 200 mL) under agitation to yield the aqueous extract (1.892 g). 
The remaining sponge residue (3.572 g, dry weight) was extracted with MeOH (3 x 150 mL) and 
subsequently with DCM (3 × 150 mL) under the same conditions. Combined MeOH and DCM 
extracts were evaporated to dryness by a rotary evaporator to yield the crude organic extract (328 
mg) that showed very strong anticancer activity against multiple cancer cell lines. This extract was 
partitioned between MeOH (100 mL) and n-hexane (100 mL) to yield MeOH (190 mg) and n-hexane 
(120 mg) subextracts. The MeOH-soluble portion, which exhibited strong anticancer activity was 
fractionated on a Chromabond SPE C18 cartridge. The elution with a step gradient MeOH:H2O 
mixture (0% to 100%) afforded 8 fractions (M1–M8), of which the anticancer activity was tracked to 
six fractions M2–M5, M7, and M8. RP-HPLC separation of M2 (18 mg) on the analytical Synergi 
column gradient of H2O:MeCN (77:22), with 0.1% TFA, flow 1.0 mL/min yielded compound 1 (1.5 
mg, tR 5.5 min). RP-HPLC analysis of M3 (10 mg) on the same column (gradient of H2O:MeCN from 
80:20 to 70:30 in 25 min, with 0.1% TFA, flow 1.0 mL/min) afforded compounds 5 (0.3 mg, tR 15.2 
min) and 3 (0.3 mg, tR 19.0 min). M4 (16 mg) was further fractionated on a Chromabond SPE C18 
cartridge to furnish 5 subfractions (M4-1 to M4-5). The subfraction M4-1 (4.4 mg) was further 
purified by RP-HPLC equipped with an analytical C18 column using a gradient of H2O:MeCN 
(87:13 to 80:20, 0–16 min, 80:20 to 74:26, 16–27 min, with 0.1% TFA, flow 1.0 mL/min) to yield 
compounds 4 (0.1 mg, tR 18.9 min) and 2 (0.1 mg, tR 20.5 min). RP-HPLC separation of the nonpolar 
fraction M8 (23.9 mg) (gradient of H2O:MeCN 25:75 to 0:100, 0–15 min, with 0.1% TFA, flow 1.0 
mL/min) on an analytical C18 column yielded compound 6 (0.2 mg, tR 14.9 min). Each purified 
compound was further checked, individually, for enantiopurity by RP-DAD-HPLC on a chiral 
analytical column using a gradient of H2O:MeCN (99:1 to 0:100, 0–15 min, with 0.1% TFA, flow 1.5 
mL/min).  
(−)-(1R,2S,6R,8S)-Discorhabdin L (1): Greenish film; [α]20D = −71 (c 0.1, MeOH); 1H NMR (CD3OD, 600 
MHz) and 13C NMR (CD3OD, 150 MHz) Tables 2 and 3; HR-ESIMS found m/z [M + H]+ 352.0748, 
C18H14N3O3S requires 352.0756.  
(+)-(5R,6S,8S)-Discorhabdin A (2): Orange film; [α]20D = +197 (c 0.01, MeOH); HR-ESIMS found m/z [M 
+ H]+ 416.0065, C18H1579BrN3O2S requires 416.0068. 
(+)-(6S,8S)-Discorhabdin Q (3): Orange film; [α]20D = +568 (c 0.1, MeOH); HR-ESIMS found m/z [M + 
H]+ 411.9733, C18H1179BrN3O2S requires 411.9759.  
Mar. Drugs 2019, 17, 439 15 of 19 
 
(−)-(2R,6R,8S)-2-Bromodiscorhabdin D (4): Greenish film; UV (MeOH) λmax 250 (є 13840), 285 (є 11184), 
325 (є 7947), 403 (є 7802) nm; [α]20D = −246 (c 0.05, MeOH); IR (film) vmax 2922, 2852, 1657, 1533, 1514, 
1432, 1230 cm-1; 1H NMR (CD3OD, 600 MHz) and 13C NMR (CD3OD 150 MHz) Tables 2 and 3; HR-
ESIMS found m/z [M + H]+ 413.9913, C18H1379BrN3O2S requires 413.9912.  
(−)-(1R,2S,6R,8S)-1-Acetyl-discorhabdin L (5): Greenish film; UV (MeOH) λmax 250 (є 24822), 283 (є 
17019), 325 (є 11700), 403 (є 11169) nm; [α]20D = −420 (c 0.01, MeOH); IR (film) vmax 2926, 2854, 1747, 
1653, 1621, 1560, 1528, 1412, 1201 cm-1; 1H NMR (CD3OD, 600 MHz) and 13C NMR (CD3OD, 150 
MHz) Tables 2 and 3; HR-ESIMS found m/z [M + H]+ 394.0816, C20H16N3O4S requires 394.0861.  
(+)-(1R,2S,6R,8S)-1-Octacosatrienoyl-discorhabdin L (6): Greenish film; UV (MeOH) λmax 203 (є 19890), 
249 (є 19439), 285 (є 15904), 325 (є 13122), 403 (є 11543) nm; [α]20D = +541 (c 0.1, MeOH); IR (film) vmax 
3007, 2927, 2855, 1739, 1678, 1621, 1566, 1527, 1441, 1206, 1185, 1135 cm-1; 1H NMR (CD3OD, 600 
MHz) and 13C NMR (CD3OD, 150 MHz) Tables 2 and 3; HR-ESIMS found m/z [M + H]+ 752.4452, 
C46H62N3O4S requires 752.4461. 
4.4. UPLC-QToF-MS/MS Analysis 
The six active C18 SPE fractions of the MeOH soluble portion were analyzed on an ACQUITY 
UPLC I-Class System coupled to the Xevo G2-XS QToF Mass Spectrometer (Waters®, Milford, 
Massachusetts, USA) equipped with an electrospray ionization (ESI) source operating with a 
positive polarity at a mass range of m/z 50–1600 Da. The 0.1 mg/mL MeOH solution of the fractions 
were filtered through a 0.2 µm PTFE syringe filter (Carl Roth, Karlsruhe, Germany) and then 
injected (injection volume: 1.0 µL) into the system equipped with Acquity UPLC HSS T3 column 
(high-strength silica C18, 1.8 µm, 100 × 2.1 mm I.D., Waters®) operating at 40 °C. Separation was 
achieved with a binary LC solvent system controlled by MassLynx® (version 4.1) using mobile 
phase A 99.9% water/0.1% formic acid (ULC/MS grade) and B 99.9% ACN/0.1% formic acid 
(ULC/MS grade), pumped at a rate of 0.6 mL/min with the following gradient: Initial, 1% B; 0.0–12.0 
min to 100% B; 12.0–13.0 min 100% B, and a column reconditioning phase until 15 min.  
ESI conditions were set with the capillary voltage at 0.8 kV, sample cone voltage at 40.0 V, 
source temperature at 150 °C, desolvation temperature at 550 °C, cone gas flow in 50 L/h, and 
desolvation gas flow in 1200 L/h. MS/MS setting was linear collision energy (CE) at 30 eV. As a 
control, solvent (methanol) was injected. MassLynx® (Waters®, V4.1) was used to analyze the 
achieved MS and MS2 data. 
4.5. Molecular Networking 
The network was created using the UPLC-HRMS/MS data generated from the six active MeOH 
subfractions of L. biformis. All raw MS/MS data were converted from files (.raw) to mzXML file 
format using MSConvert (Version 3.6.10051, Vanderbilt University, Nashville, TN, USA). The 
converted data files were uploaded to the Global Natural Products Social molecular networking 
(http://gnps.ucsd.edu) platform using FileZilla (https://filezilla-project.org/) and a molecular 
network was created using the online workflow at GNPS [22]. The data were filtered by removing 
all MS/MS peaks within +/− 17 Da of the precursor m/z. MS/MS spectra were window filtered by 
choosing only the top 6 peaks in the +/− 50Da window throughout the spectrum. The data were 
then clustered with MS-Cluster with a parent mass tolerance of 0.1 Da and an MS/MS fragment ion 
tolerance of 0.05 Da to create consensus spectra. Further, concensus spectra that contained less than 
2 spectra were discarded. A network was then created where edges were filtered to have a cosine 
score above 0.6 and more than 3 matched peaks. Further edges between two nodes were kept in the 
network if and only if each of the nodes appeared in each other’s respective top 10 most similar 
nodes. The spectra in the network were then searched against GNPS’ spectral libraries. The library 
spectra were filtered in the same manner as the input data. All matches kept between network 
spectra and library spectra were required to have a score above 0.7 and at least 6 matched peaks. 
The output molecular networking data were analyzed and visualized using Cytoscape (ver. 3.61) 
[46].  
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4.6. Cytotoxicity Assay 
Crude extract of L. biformis and downstream fractions were tested in vitro at a final 
concentration of 100 µg/mL against 6 human cancer cell lines, Hep G2 (liver cancer cell line, DSMZ, 
Braunschweig, Germany), HT29 (colorectal adenocarcinoma cell line, DSMZ, Braunschweig, 
Germany), A375 (malignant melanoma cell line, CLS, Eppelheim, Germany), HCT116 (colon cancer 
cell line, DSMZ, Braunschweig, Germany), A549 (lung carcinoma cell line, CLS, Eppelheim, 
Germany), and MDA-MB231 (human breast cancer line, CLS, Eppelheim, Germany). Cells were 
supplemented at 37 °C and 5% CO2 in RPMI 1640 medium (Life Technologies, Darmstadt, 
Germany) with 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin. A stock 
solution of 20 mg/mL in DMSO was prepared for each test sample. After 24 h incubation in 96-well 
plates, the medium in the cells was replaced by 100 µL fresh medium containing the test samples 
and cells were incubated for another 24 h at 37 °C. Doxorubicin was used as positive control, while 
0.5% DMSO and growth media served as negative controls. All samples were prepared in 
duplicates. The assay was performed according to the manufacturer’s instructions (Promega, 
Madison, WI, USA). Cells were incubated for 2 h at 37 °C and fluorescence at an excitation 
wavelength of 560 nm and emission at 590 nm was measured. For the determination of IC50 values, 
a dilution series of the extracts were tested following the same procedure as described before. IC50 
values were calculated by using Excel to determine the concentration that shows 50% inhibition of 
the viability. 
4.7. Molecular Modeling and Docking 
Molecular modeling was performed on a DELL Precision T3610 four core workstation using 
Schrödinger Maestro (version 11.3, 2017, Schrödinger, LLC, New York, NY, USA). The following 
RCSB protein data bank (pdb) crystal structures were used for modeling studies: 1T8I, 3QX3, 5EK2, 
5XE1, 6AZV, 6AZW. Each protein structure was initially prepared by standard settings of the 
Protein Preparation Wizard 2015-4 (Epik version 2.4, Schrödinger, LLC, 2015; Impact version 5.9, 
Schrödinger, LLC, 2015; Prime version 3.2, Schrödinger LLC, 2015). For energy minimizations of the 
small-molecule ligands, MacroModel (version 11.0, Schrödinger, LLC, 2015) was used. Ionization 
states and tautomers were generated with LigPrep (version 3.6, Schrödinger, LLC, 2015). Ligand 
docking and receptor grid generation was performed with Glide (version 6.9, Schrödinger, LLC, 
2015). Figures and ligand interaction diagrams (LID) were generated by Maestro. 
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compounds 1–6. ECD spectra of compounds 1,4,5, and 6.  
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